Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05353153
Other study ID # 2021_0409
Secondary ID 2021-A02139-32
Status Recruiting
Phase N/A
First received
Last updated
Start date June 3, 2022
Est. completion date September 2024

Study information

Verified date April 2022
Source University Hospital, Lille
Contact Sara BALAGNY, MD
Phone 0320445962
Email sara.balagny@chru-lille.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research investigates the impact of a hypnosis-based intervention in alleviating state anxiety in Preterm Premature Rupture of Membranes (PPROM). Our main hypothesis is that a two-session intervention can decrease anxiety for pregnant women with PPROM compared to usual care. This research also studies the impact of the experience of a PPROM during a pregnancy on several variables such as perinatal depression, pregnancy-related anxiety, bonding and childbirth experience, as well as control and pain perceived during chilbirth. Our hypotheses are that the experience of PPROM negatively influences these variables, and that this impact is alleviated by the hypnosis-based intervention for the experimental group.


Recruitment information / eligibility

Status Recruiting
Enrollment 94
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Being an adult French-speaking woman, - primi or multipara, - less than 33 weeks and 6 days of amenorrhea - having being diagnosed with PPROM Exclusion Criteria: - Women cognitively impaired or with important hearing issues, - being placed under protective measures, - caring more than one fetus, - having a severe, preexisting or triggered during the pregnancy, - psychiatric pathology, - caring a fetus with an abnormality having required further medical investigations, or participating in another clinical trial comprising an intervention measuring psychological variables

Study Design


Related Conditions & MeSH terms


Intervention

Other:
hypnosis
Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
standart care
no intervention no hypnosis

Locations

Country Name City State
France Hop Claude Huriez, Had, Chu Lille Lille

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Lille Laboratory of Psychopathology and Health Processes, University of Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary State anxiety by STAI-Y-A scale change in anxiety-status level between baseline and 3-week (+/- 1 week) the STAI-Y-A scale, which is a 20-item self-questionnaire evaluating anxiety at the present time. The measurement is done on a Likert scale from 1 to 4 (each number corresponding to a value, 1 being the lowest and 4 the highest for each item, score ranging from 20 to 80). between baseline and 3-week (+/- 1 week) prenatal measurement
Secondary Pregnancy related anxiety by PRAQ-R2 The Pregnancy related Anxiety Questionnaire revised is a 10-item Self-administered questionnaire that assesses specific prenatal anxiety. On a Likert scale ranging from 1 to 5 (each number corresponding to a value, 1 being the lowest and 4 the hghest for each item, score ranging from 10 to 50) 1 time at baseline
Secondary Pregnancy related anxiety by PSAS The Postnatal Specific Anxiety Scale (PSAS) is a 44-item self-administered questionnaire that assesses specific postpartum anxiety. On a Likert scale ranging from 1 to 4 (each number corresponding to a value, 1 being the lowest and 4 the highest for each item, score ranging from 44 to 176) At 4 time points: 2 in the prenatal period (at baseline and 3 weeks after) and 2 in the postnatal period (at 1 day to 7 days postpartum and at 4 to 6 weeks postpartum)
Secondary State anxiety by STAI-Y-A The change in anxiety-status level between the baseline measurement and the postnatal measurements between the baseline measurement and the postnatal measurements ( at 1 day to 7 days postpartum and at 4 to 6 weeks postpartum)
Secondary Perinatal depression by EPDS the EPDS is a self-administered questionnaire assessing the presence of depressive symptoms in the pre- and postnatal period. This scale has 10 items with a score ranging from 0 to 30, the threshold score is 10.5 At 3 time points: 2 in the prenatal period (at baseline and 3 weeks after) and 1 in the postnatal period ( at 4 to 6 weeks postpartum)
Secondary Childbirth experience by QEVA The french version of the questionnaire for assessing childbirth experience QACE.
this is a 17 item self-questionnaire evaluating the childbirth experience, with a score ranging from 0 to 51, the highest score being the more negative experience.
At 1 day to 7 days postpartum
Secondary Labor agentry by LAS ( Labor Agentry Scale) this is a 32-item self-administered questionnaire evaluating the perceived control during childbirth. the score tanges from 32 to 210, the highest score evaluating a higher perceived control. at one point at 1day to 7 days postpartum
Secondary Perinatal bonding by PAI the Prenatal Attachement Inventory (PAI) is a 21-item self-administered questionnaire assessing bonding in the prenatal period, on a Likert scale ranging from " almost nerver" to almost always", with a total score ranging from 21 to 84, a higher score evaluating a higher bonding At one point at baseline
Secondary postnatal bonding by PPBQ The Postpartum Bonding Questionnaire (PPBQ) is a 22-item self-administered questionnaire assessing bonding in the postpartum period, on a Likert scale ranging from "always" to "never", with a total score ranging from 0 to 110. A cut-off score of 26 has been indicated as the onset of bonding disorder, and 40 for more severe disorders in bonding with the child at 4 to 6 weeks postpartum
Secondary Pain Visual Analog Scale by EVA The VAS (Visual Analog Scale) is a self-assessment scale of pain, on a 10cm ruler graduated in mm, ranging from "No pain" to "Maximum pain imaginable". At 2 time points in the postnatal period : at 1 day to 7 days postpartum and at 4 to 6 weeks postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT04963465 - The Accuracy of Amniotic Fluid Ferning in the Second Trimester in the Diagnosis of Preterm Prelabor Rupture of Membranes
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT04294069 - Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial Phase 4
Recruiting NCT03976063 - Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation Phase 3
Completed NCT01503606 - Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane Phase 3
Recruiting NCT04590677 - Prediction of the Onset of Term and Preterm Labour
Recruiting NCT04110704 - Cerclage After Full Dilatation Caesarean Section N/A
Completed NCT03473210 - The Value of Amniopatch in Preterm Premature Rupture of Membranes N/A
Not yet recruiting NCT05328817 - Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes N/A
Completed NCT03814278 - Bed Rest After Preterm Premature Rupture of the Membranes N/A
Completed NCT04807543 - Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes Phase 2
Not yet recruiting NCT05207800 - Predictive Value of Maternal Serum Pentraxin 3 (PTX 3) and Heparin-binding Protein (HBP) for Chorioamnionitis in Preterm Premature Rupture of Membranes
Recruiting NCT04705935 - Amniochorionic Membrane Cells in the Maternal Blood as a Biomarker for Preterm Birth
Active, not recruiting NCT06074601 - MIRACLE of LIFE Study
Recruiting NCT04516226 - Vaginal Cleansing With Chlorhexidine Gluconate in Women With Preterm Pre-labor Rupture of Membranes N/A
Recruiting NCT03306719 - mtDNA as Novel Biomarker for Intra-amniotic Infection N/A
Not yet recruiting NCT06377397 - Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates Phase 3
Completed NCT04413019 - Domiciliary Versus Hospital Management of PPROM